Trial reportESMO open2026
Pembrolizumab combined with nab-paclitaxel and platinum in recurrent/metastatic HNSCC: efficacy, safety, and survival predictive model.
Trial report in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04857164 (A Prospective Study of Pembrolizumab Combined with Chemotherapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Study of Pembrolizumab Combined with Chemotherapy (cisplatin or Carboplatin + Albumin-bound Paclitaxel) in First-line Therapy for Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains a therapeutic challenge. This study evaluated the triplet combination of pembrolizumab, nab-paclitaxel, and platinum in R/M HNSCC and developed a practical predictive model for treatment stratification. PATIENTS AND
methodsIn this single-arm phase 2 study (NCT04857164), treatment-naïve patients with R/M HNSCC received pembrolizumab (200 mg), nab-paclitaxel (260 mg/m
resultsFrom April 2021 to February 2025, a total of 148 patients with R/M HNSCC were enrolled. At a median follow-up of 23.0 months [95% confidence interval (CI) 19.4-29.6], objective response rate was 64.2% (95/148) and disease control rate was 93.2% (138/148). Median progression-free survival (PFS) was 12.7 months [95% confidence interval (CI) 10.2-14.7) and median overall survival (OS) was 21.8 months (95% CI 18.9-35.7). Hypothyroidism was the most common immune-related adverse event (27%, 40/148), with 39 grade 1-2 and one grade 3 case. The predictive model based on seven clinical parameters achieved excellent predictive accuracy, with time-dependent AUCs of 0.826-0.906 (training) and 0.753-0.919 (test) for PFS prediction, and 0.682-0.799 (training) and 0.784-0.908 (test) for OS. Higher model scores delineated a high-risk phenotype marked by nutritional depletion and chronic inflammation activation, mechanistically explaining the associated poor outcomes.
conclusionsThis study demonstrated encouraging efficacy and a manageable safety profile of pembrolizumab-nab-paclitaxel-platinum combination in R/M HNSCC. Furthermore, we established a predictive model using routine clinically accessible parameters, offering a practical and cost-effective tool for treatment stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.